שולי רווח תפעולי ממכירות: Immunocore Holdings (IMCR)

While a steady inflow of funds may seem debatable, tracking the operating margin confirms the resilience of the Immunocore Holdings plc (IMCR) business. Current profitability, where -6.80 is the relevant metric value, is based on sales of KIMMTRAK for the treatment of uveal melanoma. Revenues also rely on T-cell receptors for oncology. Medical recognition of these innovations ensures the long-term protection of cash flows.
Immunocore Holdings plc - פילוחים אנליטיים ומדדי מפתח (IMCR)

The monopoly status of its uveal melanoma treatment provides Immunocore Holdings plc (IMCR) with significant pricing power. This metric measures the operating profit margin as a percentage of revenue, excluding the impact of taxes and debt obligations. The trend in operating profit percentage demonstrates management's ability to convert revenue into actual income. A stable trend confirms the effectiveness of cost controls while maintaining maximum therapy pricing. This justifies the resilience of the business's fundamental valuation.